Weight-loss drug Wegovy cuts cardiovascular risk by 20% in major trial

Wegovy reduced risk of heart attack, stroke, and cardiovascular death by 20% compared to placebo in trial of 17,000 overweight or obese adults.
Trial results exceed expectations and highlight potential medical benefits of Wegovy beyond just weight loss.
Novo Nordisk seeking regulatory approval for expanded Wegovy labeling based on cardiovascular findings.
Positive trial data may increase pressure on insurers to cover costly obesity medications like Wegovy.
Findings could transform medical understanding of obesity as disease requiring chronic treatment.